Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Desktop MRI System Designed for Easy Use, Easy-to-Site Preclinical and Molecular Imaging

By LabMedica International staff writers
Posted on 30 Sep 2010
A new easy-to-use 1.0 Tesla desktop magnetic resonance imaging (MRI) scanner combines simplicity with compact dimensions brings preclinical MRI scanning within reach for a wider range of molecular imaging laboratories. More...


Bruker Corp. (Billerica, MA, USA) announced the introduction of the Icon MRI system, with its innovative cryogen-free permanent magnet from Aspect Magnet Technologies (Netanya, Israel) and high-performance Avance III spectrometer technology with industry-leading preclinical MRI software ParaVision from Bruker, the new Icon system delivers powerful performance and ease of use at an attractive price point.

The Icon is a state-of-the-art and cost-effective MRI instrument for routine preclinical and molecular imaging in biomedical and pharmaceutical applications. Bruker's industry standard MRI software ParaVision guarantees access to a wide range of acquisition and processing tools for in vivo and material science MRI applications. Optional software modules enable the Icon to perform the latest MRI applications, such as relaxometry mapping, fast echo-planar imaging, ultra-short echo time lung imaging, or contrast agent research. As an educational tool, students will find the ParaVision software intuitive, whether it is used to perform research-imaging protocols, or to learn programming of MRI methods.

The new compact shielded permanent magnet with its very small footprint results in an easy to site and install MRI system with almost negligible running costs. Even with a field strength of 1 Tesla, the Icon has zero magnetic fringe field enabling safe location of the system in any facility and for use by any operator. No additional magnetic or radiofrequency (RF) shielding is required for the implementation in the lab. Icon benefits from the Avance III sophisticated digital RF architecture as the technologic basis for the latest MRI applications of today's and tomorrow's preclinical questions.

Dr. Wulf I. Jung, managing director of Bruker BioSpin MRI, GmbH, commented, "High-performance desktop MRI systems have the potential to deliver new research applications to the field of preclinical and molecular imaging. The Icon system is aimed at easy, routine MRI workflows with a compact footprint, low running costs, no magnetic stray fields, and push-button imaging performance, based on the latest Bruker spectrometer and software technology, in order to enable new research groups to enter this fascinating field of preclinical and materials MRI.”

Related Links:

Bruker
Aspect Magnet Technologies





Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Collection and Transport System
PurSafe Plus®
Rapid Molecular Testing Device
FlashDetect Flash10
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.